Tag
This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.
The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.
The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metast
Statin exposure is linked to improved overall survival in prostate cancer patients treated with apalutamide but raises the risk of severe cardiac adverse events due to underlying cardiovascular conditions.
Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.
The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.
Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.
The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.
